Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trialYuankai Shi, Zhiyue Rao, Jian Zhang et al.|Nature Medicine|2025Cited by 30
Uncommon/rare oncogenic drivers in non‐small cell lung cancer: Consensus and contentionYi‐Long Wu, Qitao Yu, Shun Lü et al.|Medicine Advances|2023Cited by 8